XML 45 R31.htm IDEA: XBRL DOCUMENT
v3.19.1

Collaboration and Licensing Revenue (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2019 and 2018.
| Three Months Ended March 31,
| 2019 |  | 2018
ZIOPHARM Oncology, Inc. | $ | 1,166 |  |  | $ | 5,377 |
Ares Trading S.A. | — |  |  | 2,423 |
Oragenics, Inc. | 203 |  |  | 125 |
Intrexon T1D Partners, LLC | — |  |  | 1,328 |
Intrexon Energy Partners, LLC | 977 |  |  | 1,197 |
Intrexon Energy Partners II, LLC | 504 |  |  | 378 |
Genopaver, LLC | 294 |  |  | 1,315 |
Fibrocell Science, Inc. | 383 |  |  | 293 |
Persea Bio, LLC | (1,272 | ) |  | 209 |
Harvest start-up entities (1) | 2,723 |  |  | 3,197 |
Other | 992 |  |  | 4,006 |
Total | $ | 5,970 |  |  | $ | 19,848 |
(1) For the three months ended March 31, 2019 and 2018, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the three months ended March 31, 2018, revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.
Summary of Deferred Revenue | Deferred revenue consists of the following:
| March 31, 2019 |  | December 31, 2018
Collaboration and licensing agreements | $ | 65,135 |  |  | $ | 63,284 |
Prepaid product and service revenues | 3,157 |  |  | 2,933 |
Other | 2,899 |  |  | 3,547 |
Total | $ | 71,191 |  |  | $ | 69,764 |
Current portion of deferred revenue | $ | 17,149 |  |  | $ | 15,554 |
Long-term portion of deferred revenue | 54,042 |  |  | 54,210 |
Total | $ | 71,191 |  |  | $ | 69,764 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of March 31, 2019 and December 31, 2018, including the estimated remaining performance period as of March 31, 2019.
| Average Remaining Performance Period (Years) |  | March 31, 2019 |  | December 31, 2018
ZIOPHARM Oncology, Inc. | 0.5 |  | $ | 628 |  |  | $ | 1,214 |
Oragenics, Inc. | 5.2 |  | 5,669 |  |  | 5,810 |
Intrexon Energy Partners, LLC | 5.0 |  | 9,659 |  |  | 10,267 |
Intrexon Energy Partners II, LLC | 5.7 |  | 13,556 |  |  | 14,060 |
Genopaver, LLC | 5.0 |  | 1,238 |  |  | 1,175 |
Fibrocell Science, Inc. | 5.9 |  | 17,192 |  |  | 17,519 |
Persea Bio, LLC | 5.8 |  | 4,070 |  |  | 2,697 |
Harvest start-up entities (1) | 5.9 |  | 7,260 |  |  | 7,644 |
Other | 2.0 |  | 5,800 |  |  | 2,898 |
Total |  |  | $ | 65,072 |  |  | $ | 63,284 |
(1) As of March 31, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationandLicensingRevenueTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration